Background-Regional differences in the profile and prognosis of non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients treated with medical management after angiography remain uncertain. Methods and Results-Using data from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndromes (EARLY ACS) trial, we examined regional variations in the use of an in-hospital medical management strategy in NSTE ACS patients who had significant coronary artery disease (CAD) identified during angiography, factors associated with the use of a medical management strategy, and 1-year mortality rates. Of 9406 patients, 8387 (89%) underwent angiography and had significant CAD; thereafter, 1766 (21%) were treated solely with a medical management strategy (range: 18% to 23% across 4 major geographic regions). Factors most strongly associated with a medical management strategy were negative baseline troponin values, prior coronary artery bypass grafting, lower baseline hemoglobin values, and greater number of diseased vessels; region was not a significant factor. One-year mortality was higher among patients treated with a medical management strategy compared with those who underwent revascularization (7.8% versus 3.6%; adjusted hazard ratio, 1.46; 95% CI, 1.21-1.76), with no significant interaction by region (interaction probability valueϭ0.42). 
S ince 2002
, clinical practice guidelines in the United States and Europe have endorsed an early invasive management strategy for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), consisting of early angiography followed by either anatomy-driven revascularization or conservative medical management for patients without revascularization options. 1, 2 Data from the international Global Registry of Acute Coronary Events (GRACE) registry demonstrated trends for increasing use of both angiography and percutaneous coronary intervention (PCI) for NSTE ACS patients from 1999 to 2006 across 14 countries, with a concomitant decline in the use of a medical management strategy without revascularization. 3 Although an analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) initiative demonstrated similar findings only in the United States, regional differences were not reported in the GRACE analysis; thus, regional variations in the use of a medical management strategy after early angiography have not been well characterized in contemporary practice. 4 Given the increasing use of early invasive management strategies for NSTE ACS patients over the last decade, the profile and prognosis of patients who are solely treated with a medical management strategy after early angiography may have changed. It also remains unknown whether the clinical factors associated with a medical management strategy and the clinical outcomes of patients treated with this strategy differ across geographic regions in contemporary practice. 5 Therefore, we examined the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndromes (EARLY ACS) trial database to (1) evaluate regional variations in use of an in-hospital medical management strategy among patients with significant coronary artery disease (CAD) identified during early angiography, and (2) determine whether there were regional differences in the clinical factors associated with a medical management strategy and the 1-year mortality risks associated with this treatment strategy.
WHAT IS KNOWN
• A proportion of non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients who undergo early catheterization and are found to have significant coronary artery disease are medically managed without subsequent revascularization.
• NSTE ACS patients treated with a medical management strategy are typically older, more commonly have undergone prior revascularization procedures, and have a greater burden of comorbidities.
• NSTE ACS patients treated with a medical management strategy have an increased risk of adverse outcomes, including mortality through at least 1 year of follow up.
WHAT THE STUDY ADDS
• The proportion of NSTE ACS patients with significant coronary artery disease identified on early catheterization that are subsequently medically managed is similar across geographic regions (approximately 20%).
• Factors associated with the use of a medical management strategy and the increased risk of mortality through 1 year with a medical management strategy are similar across geographic regions.
• The profile and prognosis of medically managed NSTE ACS patients are similar across the globe and have implications for the design and conduct of future trials targeting NSTE ACS patients.
Methods

Study Population
Patients with NSTE ACS were enrolled in the EARLY ACS trial from 2004 to 2008 in 29 countries worldwide. Inclusion criteria for the EARLY ACS trial were ischemic symptoms at rest lasting at least 10 minutes within the previous 24 hours, randomization within 12 hours of initial hospital presentation, planned invasive strategy no sooner than 12 hours after randomization, and at least 2 of the following 3 enrichment criteria: age Ն60 years, positive cardiac biomarkers, or ST-segment depression or transient ST-segment elevation. 6 Patients in this analysis underwent angiography and were found to have significant CAD (at least 1 coronary lesion Ͼ50% in at least 1 major epicardial coronary artery). From the original sample of 9406 patients randomized in the EARLY ACS trial, we excluded 1019 (11%) patients who either did not undergo angiography (nϭ240) or who were found to have insignificant, nonobstructive CAD during angiography (nϭ779), resulting in an analysis cohort of 8387 patients.
The use of guideline recommended medications during the initial hospitalization was recommended for patients included in the trial, but was not mandated by the study protocol. Most patients received aspirin, clopidogrel, anticoagulants, and anti-ischemic medications during the acute hospitalization, as detailed in the main study manuscript. 6 
Designation of Geographic Regions
Among the 29 countries participating in the EARLY ACS trial, 4 geographic regions were prespecified and used to evaluate regional differences in the main trial results. 6 The 4 designated regions included North America (United States and Canada), Western Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Sweden, Portugal, Spain, Switzerland, United Kingdom), Eastern Europe (Czech Republic, Poland, Hungary, Finland, Russia), and the Middle East, Africa, or Asia-Pacific (Israel, Turkey, Hong Kong, India, Malaysia, Singapore, South Africa, Australia, New Zealand).
Outcomes Comparisons
We evaluated clinical factors and angiographic findings associated with the selection of an in-hospital medical management strategy, as well as mortality rates through 1 year. All baseline clinical characteristics, time intervals from hospital arrival to randomization and from randomization to angiography, and diagnostic angiographic findings (extent of CAD and left ventricular ejection fraction [LVEF]) were evaluated as potential factors associated with use of an in-hospital medical management strategy, because these variables would have been known to the treating physician before the decision to treat with revascularization or a medical management strategy was made. We chose to focus on 1-year mortality rates in the clinical outcomes comparisons because the maximum duration of follow-up for the EARLY ACS trial was 1 year and because (re)infarction events were captured only during the first 30 days and primarily occurred during the periprocedural timeframe for patients who underwent PCI or coronary artery bypass grafting (CABG). 6 Therefore, we felt that a comparison of death or (re)infarction rates between medically managed and revascularized patients would be too confounded for the purposes of this analysis.
Statistical Analyses
Baseline clinical characteristics and angiographic findings among patients treated with an in-hospital medical management strategy were compared with those of patients undergoing revascularization separately by region, but statistical tests were not performed for these comparisons, as the main purpose was to characterize the 2 patient populations, which were expected to be different.
A predictive model was created to determine factors associated with an in-hospital medical management strategy (versus revascularization) using logistic regression methodology. Baseline demographic and clinical factors, qualifying event details, and precatheterization findings were used as collected on the case report form. The covariate list for this model included the following: age, weight, sex, race, smoking status, diabetes, hypertension, family history of CAD, prior medical or surgical history of vascular disease (CAD, angina, myocardial infarction, peripheral vascular disease, stroke, transient ischemic attack, PCI, CABG), presenting blood pressure (systolic and diastolic), presenting heart rate, Killip class at presentation, serum creatinine, hemoglobin, hematocrit, and white blood cell count. Qualifying event variables included elevated cardiac markers (creatine kinase-MB and troponin levels: positive or negative relative to the site's upper limit of normal) and ischemic ECG changes (ST-segment depression Ͼ0.1 mV or transient ST-segment elevation Ͼ0.1 mV). Prerandomization medications (angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, aspirin, ␤-blockers, nitrates, morphine, proton-pump inhibitors, and statins) also were included. Additionally, because noncatheterization patients were excluded from this analysis, the timing from randomization to catheterization, ejection fraction, and number of significantly diseased vessels also were included.
The most appropriate functional form of each continuous variable was selected into the model. Model development used stepwise selection and bootstrap techniques to identify the predictive variables. Variables were selected for entry at a significance level of Pϭ0.10, and retained at Pϭ0.05. To prevent loss of observations during multivariable modeling, multiple imputation was performed for all covariates. After all significant covariates were included, region was added to the model. A directed approach to interactions was used. Interactions with region were tested for the main effects findings of prior CABG, number of diseased vessels, sex, and elevated baseline troponin and region. Additionally, an interaction with region was tested for number of diseased vessels and prior CABG.
The use of evidence-based medications at hospital discharge was compared among medically managed versus revascularized patients within each geographic region to characterize regional differences in treatment patterns among the 2 groups.
Mortality rates through 1 year were determined by the KaplanMeier method and were compared between patients undergoing revascularization and those treated with medical management in the overall sample, among those patients with 3-vessel or left-main disease on angiography (because these patients would be considered those to benefit the most from early revascularization), as well as within each of the 4 regions analyzed. An adjustment model for 1-year mortality was developed using Cox proportional hazards regression to determine the adjusted risk of mortality for patients treated with an in-hospital medical management strategy versus those who underwent revascularization. Predictive modeling steps as described for the logistic analysis of factors associated with the use of an in-hospital medical management strategy were employed during the development of this model using the same variables, with the exception of precatheterization and prerandomization medications in the covariate list. Additionally, risk factors from the GRACE 6-month mortality models also were included. 7 An interaction term with region was added to the model to determine whether the 1-year mortality results differed by region.
Results
Use of a Medical Management Strategy by Region
The approximate proportional enrollment of patients in this analysis population across the geographic regions was 31% in North America, 40% in Western Europe, 11% in Eastern Europe, and 18% in Middle East/Africa/Asia-Pacific. Among the 8387 patients with significant CAD identified during angiography, 1766 (21%) were treated with an in-hospital medical management strategy, 5402 (64%) underwent inhospital PCI, 1174 (14%) underwent in-hospital CABG, and 45 (0.5%) had both in-hospital PCI and CABG. An inhospital medical management strategy was used in 22.6% of patients from North America, 20.2% from Western Europe, 18.4% from Eastern Europe, and 22.0% from Middle East/ Africa/Asia-Pacific (probability value for comparison of proportion of patients medically managed within each regionϭ0.02).
Patient Characteristics and Angiographic Findings
Patients treated with an in-hospital medical management strategy were older, more often female, more frequently had diabetes mellitus, prior myocardial infarction, prior PCI, and prior CABG, less often had an elevated baseline troponin value or ischemic ECG changes, and had lower baseline hemoglobin and estimated creatinine clearance compared with patients who underwent revascularization ( Table 1 ). The median length of stay during the initial hospitalization was shorter for medically managed patients compared with revascularized patients. While the frequency of these clinical characteristics differed among regions, the differences between the medically managed versus revascularized patients appeared to be similar within each region. Patients treated with an in-hospital medical management strategy also more frequently had 3-vessel CAD and left-main disease on angiography and an LVEF Ͻ30%, with similar findings within each region (Table 2) .
Factors Associated With Selection of a Medical Management Strategy
The factors most strongly associated with an in-hospital medical management strategy included negative baseline troponin, prior CABG, lower baseline hemoglobin values, 3-vessel or left-main CAD identified during angiography, longer time from randomization to angiography, and lack of ischemic ECG changes at presentation ( Table 3) . The model c-statistic was 0.687, indicating only modest discrimination. Region was not significantly associated with an in-hospital medical management strategy, and interaction terms between region and other variables were not significant. The interaction term between prior CABG and extent of coronary disease was also not significant.
Discharge Medication Use
The use of evidence-based medications at discharge differed among the 4 regions analyzed, but overall and within each region (except for aspirin in Eastern Europe), patients who were medically managed were consistently less likely to receive both aspirin and clopidogrel at discharge, compared with patients who underwent revascularization (Table 4) .
One-Year Mortality Rates
Unadjusted mortality rates through 1 year were consistently higher among medically managed patients compared with those who underwent revascularization (7.8% versus 3.6%, PϽ0.0001; Figure 1 ). Similar findings were demonstrated when the population was restricted to patients with 3-vessel or left-main disease on angiography, although absolute mortality rates were higher in this restricted population, compared with the overall population (12.1% versus 5.6%, PϽ0.0001; Figure 2 ). This pattern was observed for each region: North America (7.7% versus 4.3%, Figure 3A ), Western Europe (7.3% versus 3.4%, Figure 3B ), Eastern Europe (9.4% versus 4.1%, Figure 3C ), and Middle East/Africa/Asia-Pacific (8.3% versus 2.9%, Figure 3D ). In the overall population, the MM indicates medical management; revasc, revascularization; CAD, coronary artery disease; MI, myocardial infarction; CHF, congestive heart failure; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; PVD, peripheral vascular disease; bpm, beats per min; SBP, systolic blood pressure; CrCl, creatinine clearance, ULN, upper limit of normal for site-reported troponin values. *Continuous variables expressed as medians (25th, 75th percentiles). †Determined with Cockroft-Gault formula.
adjusted risk of 1-year mortality was almost 50% higher among patients who were medically managed (adjusted HR, 1.46; 95% CI, 1.21-1.76), with no significant interaction with region (interaction probability valueϭ0.42).
Discussion
We have demonstrated that approximately 20% of NSTE ACS patients with significant CAD identified during early angiography in a contemporary, international clinical trial †Two degrees of freedom; comparison is with ejection fraction Ն50%. Note: Continuous variables are included in the model as linear splines starting at knot points as follows: baseline hemoglobin Ͻ15 mg/dL, time from randomization to angiography Ͻ20 hours, weight Ͻ85 kg, heart rate Ͼ80 beats/min, and time from hospital arrival to randomization Ͻ20 hours.
were treated solely with an in-hospital medical management strategy, with only slight regional heterogeneity. Clinical characteristics and angiographic findings predicted the use of an in-hospital medical management strategy only modestly well, with no significant differences among regions. Finally, patients who were treated with an in-hospital medical management strategy had a higher risk of mortality through 1 year compared with those who underwent in-hospital revascularization, with no interaction by region.
While significant variations in the use of early angiography and revascularization across geographic regions have been demonstrated in numerous international registries (and likely relate to the availability of cardiac catheterization facilities), factors associated with the use of a medical management strategy after early angiography have not been widely studied in contemporary practice from a regional perspective. 8, 9 A previous analysis from the Superior Yield of the New Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors (SYNERGY) trial (conducted from [2001] [2002] [2003] , which also evaluated patients with significant CAD after early angiography, demonstrated that non-United States country location, as well as prior CABG and 3-vessel CAD, were significant predictors of a medical management treatment strategy. 5 In contrast to those findings, we have demonstrated in a more contemporary trial that region was no longer a significant predictor of a medical management strategy, but that both prior CABG and multi-vessel CAD (determined by a relatively imprecise dichotomous designation on the case report form of significant coronary disease in each major epicardial vessel) remained as consistent predictors of a medical management strategy after early angiography. Despite the fact that the EARLY ACS trial was conducted after the publication of NSTE ACS guideline updates in 2002 that strongly endorsed an early invasive management strategy for high-risk patients, patients with severe CAD (ie, those with prior CABG or multi-vessel disease identified during early angiography) appeared less likely to undergo revascularization for the index ACS event in this analysis. 1, 2 Similarly, the likelihood of finding multi-vessel CAD on angiography for NSTE ACS patients has been shown to be inversely related to the use of angiography in the CRUSADE registry, which profiled the care of patients treated in routine practice in the United States from 2001 to 2006. 10 Despite these findings, the decision-making process for selecting NSTE ACS patients for both angiographic and revascularization procedures remains poorly characterized and understood. Thus, further study is needed to delineate how patient clinical and historical characteristics influence the initial decision to perform coronary angiography for NSTE ACS patients and how angiographic findings are then integrated with the other patient information in terms of deciding whether or not to perform subsequent revascularization procedures. Revascularization for NSTE ACS patients is recommended to mitigate the risk of death and recurrent ischemic events, so the prognosis of patients treated with a medical management strategy is typically much worse than those who are revascularized. 1, 2 Analyses from registries have shown that NSTE ACS patients who do not undergo angiography or who undergo angiography without subsequent revascularization have a much higher risk of both short-term and long-term mortality. 4, 11, 12 Recent analyses from NSTE ACS trials have confirmed these observations among patients who undergo early angiography but who do not proceed to subsequent revascularization procedures. 5, 13, 14 Long-term mortality rates for patients treated with a medical management strategy from these analyses of clinical trial databases were 7.7% in the SYNERGY trial (postdischarge through 1 year, only patients with significant CAD), 4.3% in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial (randomization through 1 year, all randomized patients), and 10% in the Invasive Versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) trial (postdischarge through 4 years, all randomized patients), all of which were higher than the reported mortality rates for revascularized patients in the respective trials. 5, 13, 14 The present analysis complements these observations by demonstrating a similar observation (a 1-year mortality rate of almost 8%) in medically managed NSTE ACS patients with significant CAD identified during early angiography in a more contemporary sample of invasively managed patients. Importantly, this analysis also delineates the novel finding that this risk of mortality is similar across geographic regions.
Limitations
This analysis has several limitations. First, patients treated with an in-hospital medical management strategy were highly selected based on the fact that they were healthy enough to be enrolled in a clinical trial and to be eligible for early angiography, so these results may not apply to the broader, more heterogeneous population of NSTE ACS patients treated with a medical management strategy in routine clinical practice. 11 However, the age enrichment criterion for the EARLY ACS trial led to a relatively elderly population of patients with a median age of 65 to 70 years across regions, so the proportion of medically managed patients may have been artificially enhanced by the selection of older patients for the trial. Additionally, given the fact that a negative baseline troponin value was the strongest predictor of medical management in this analysis, there may have been a portion of troponin-negative patients in this trial who were determined to be low to moderate risk by the treating physician postrandomization (despite having ischemic ST-segment changes per the inclusion criteria) and were thus selected for medical management after angiography. Second, detailed angiographic findings related to lesion complexity and risk, as well as the technical suitability of coronary lesions for revascularization, were not collected. Furthermore, the extent of coronary disease in each major epicardial coronary vessel was recorded dichotomously on the case report form only as a stenosis Ͼ50%, so we could not assess how more stringent categorizations of significant coronary disease (ie, lesions with stenoses Ͼ70%, or previously developed indices or scores of coronary disease severity) would influence this analysis. For this analysis, we could only assess how a relatively crude designation of extent of coronary disease (2-vessel, 3-vessel, and left-main disease) influenced the decision for medical management after angiography. Third, factors that influenced the treating physicians' decision making regarding the selection of a revascularization versus medical management strategy for individual patients were not collected; thus, the results of this analysis should not be construed to imply that a greater use of revascularization procedures for patients enrolled in the trial would have improved outcomes. Fourth, postdischarge revascularization procedures were not recorded through 1-year follow-up in the EARLY ACS trial; thus, we could not determine what proportion of patients who were initially medically managed subsequently underwent late revascularization procedures. Fifth, cause of death was not adjudicated, and so we could not determine how cardiovascular versus noncardiovascular deaths contributed to the increased mortality risk demonstrated in the medically managed patients. Finally, regional enrollment in the EARLY ACS trial was disproportionate, with approximately 70% of the patients enrolled in North America and Western Europe; thus, our regional analyses may have therefore been biased by the unequal proportions of patients within each region.
Conclusions
We have demonstrated a similar profile and prognosis for medically managed patients with significant CAD across different regions of the world, a finding that highlights the global similarities in the disposition and outcomes of invasively managed NSTE ACS patients who are not revascularized. These results have important implications for the conduct of future global NSTE ACS trials in that the proportion of medically managed patients will be expected to be similar across regions but will have a strong influence on expected mortality rates and resultant sample size and power calculations. As such, specific enrichment strategies for medically managed patients may need to be considered.
Finally, further study is needed to accurately determine the factors influencing physicians in their decision-making regarding the selection of a medical management strategy for NSTE ACS patients managed invasively.
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